BioMarin Pharmaceutical (NASDAQ:BMRN) +4.8% premarket on rumors that Glaxo (NYSE:GSK) is in...

BioMarin Pharmaceutical (NASDAQ:BMRN) +4.8% premarket on rumors that Glaxo (NYSE:GSK) is in advanced discussions toward a $5B buyout of BMRN. Last week, Shire (SHPGY, OTCPK:SHPGF) also was said to be stalking the company. Glaxo is already engaged in a hostile $2.6B takeover bid for Human Genome Sciences.